Novo Nordisk's NVO latest analysis showing its CagriSema injection capable of achieving 25% weight loss in average adult women adds yet another feather to the weight-loss market's cap, reinforcing the rapid pace of innovation that has defined the past year. The Danish drugmaker said its next-generation injection achieved 25% weight reduction at 68 weeks in adult women, versus just 3% for placebo, with consistent results across menopausal stages. The finding builds on a market already transformed by GLP-1 therapies, as pharma giants like Eli Lilly LLY and a few others, apart from NVO, race to establish their dominance in the global GLP-1 receptor agonist market, projected to reach $185 billion by 2033 (as per Grand View Research).
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.